Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00008385 · ClinicalTrials.gov registry record · Phase 3
Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer
A Phase 3 study, sponsored by ECOG-ACRIN Cancer Research Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,772
- Enrollment target
NCT00008385 is a Phase 3 study that has completed, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 1,772 participants.
The verdict
NCT00008385, a Phase 3 study, has completed, sponsored by ECOG-ACRIN Cancer Research Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,772 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known if selenium is effective in preventing the growth of new tumors in patients with previously resected non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying selenium to see how well it works compared to a placebo in preventing the development of second primary lung tumors in patients who have undergone surgery to remove stage I non-small cell lung cancer.
Interventions
- OTHER placebo
- DRUG selenium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,772 participants |
| Start Date | 2000-12-18 |
| Est. Completion | 2019-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00008385
The ClinicalTrials.gov registry entry for NCT00008385 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,772 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00008385 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00008385 about?
NCT00008385 is a clinical study titled "Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known if selenium is effective in preventing the growth of new tumors in patients with previously resected non-small cell lung cancer. PURPOSE: This randomized pha...
What is the current status of trial NCT00008385?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,772 participants. The study started on 2000-12-18. Estimated completion is 2019-11.
What interventions are being tested in trial NCT00008385?
The interventions under investigation include: placebo (OTHER), selenium (DRUG).
Who is sponsoring clinical trial NCT00008385?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.